Protara Therapeutics, Inc. TARA shares are down during Tuesday’s premarket session following the release of updated interim ...
Protara Therapeutics has touted a 66% complete response (CR) rate for its cell therapy among certain bladder cancer patients ...
Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor ...
Asianet Newsable on MSN
Does TARA stock’s 15% after-hours slump signal a bargain after new bladder cancer data?
The company is on track to initiate the Advanced-3 registrational trial in patients who have not previously received BCG in ...
The interim analysis of the BCG-Unresponsive cohort includes 35 evaluable participants, of whom, 22 were evaluable at six months and 15 were evaluable at 12 months as of a January 28, 2026 data cutoff ...
ANKTIVA plus BCG, with a 71% complete response rate, is the first immunotherapy to receive marketing authorization in Europe ...
Investigators reported results from the first randomized controlled trial of office-based laser photocoagulation to standard TURBT for low-grade Ta bladder tumors.
President and CEO Liz Barrett outlined the company’s urothelial cancer focus and provided an update on the commercial launch of its recently approved bladder cancer therapy during a fireside chat. RTG ...
Late-breaking KEYNOTE-B15 data show KEYTRUDA ® (pembrolizumab) plus Padcev ® (enfortumab vedotin-ejfv) significantly improved event-free survival, overall survival and pathologic complete response ...
The mother of a 3-year-old boy who died of fentanyl poisoning must remain in the Napa County jail ahead of a murder trial, a judge ruled — and the child’s father, also charged ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results